Abstract
Objective. To assess the relationship between serum concentrations of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and osteoprotegerin (OPG) and the therapeutic response to disease-modifying antirheumatic drugs (DMARD) in patients with early rheumatoid arthritis (RA). Methods. Circulating levels of TRAIL and its soluble receptor OPG were measured by ELISA in paired serum samples obtained from 66 patients with early RA at their first visit (baseline) and after 1 year of therapy. Levels of TRAIL and OPG were analyzed in relation to the clinical response, defined by the 28-joint count Disease Activity Score (DAS28). Results. Both serum TRAIL and OPG increased after DMARD therapy. Baseline levels of TRAIL, but not OPG, were significantly higher (p <0.05) in the patients that achieved a clinical response by DAS28 after 1 year of therapy, versus patients without clinical response to DMARD. Baseline serum levels of TRAIL were higher (p <0.01) in rheumatoid factor-negative patients. Conclusion. Our data suggest that the basal level of circulating TRAIL is an important determinant in the therapeutic response to DMARD in patients with early RA. The Journal of Rheumatology
| Original language | English |
|---|---|
| Pages (from-to) | 1461-1466 |
| Number of pages | 6 |
| Journal | Journal of Rheumatology |
| Volume | 37 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2010 |
Fingerprint
Keywords
- Disease modifying antirheumatic drugs
- Early rheumatoid arthritis
- Tumor necrosis factor related apoptosis inducing ligand
ASJC Scopus subject areas
- Rheumatology
- Immunology
- Immunology and Allergy
Cite this
Baseline serum concentrations of TRAIL in early rheumatoid arthritis : Relationship with response to disease-modifying antirheumatic drugs. / Secchiero, Paola; Corallini, Federica; Castellino, Gabriella; Bortoluzzi, Alessandra; Caruso, Lorenzo; Bugatti, Serena; Bosco, Raffaella; Montecucco, Maurizio; Trotta, Francesco.
In: Journal of Rheumatology, Vol. 37, No. 7, 07.2010, p. 1461-1466.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Baseline serum concentrations of TRAIL in early rheumatoid arthritis
T2 - Relationship with response to disease-modifying antirheumatic drugs
AU - Secchiero, Paola
AU - Corallini, Federica
AU - Castellino, Gabriella
AU - Bortoluzzi, Alessandra
AU - Caruso, Lorenzo
AU - Bugatti, Serena
AU - Bosco, Raffaella
AU - Montecucco, Maurizio
AU - Trotta, Francesco
PY - 2010/7
Y1 - 2010/7
N2 - Objective. To assess the relationship between serum concentrations of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and osteoprotegerin (OPG) and the therapeutic response to disease-modifying antirheumatic drugs (DMARD) in patients with early rheumatoid arthritis (RA). Methods. Circulating levels of TRAIL and its soluble receptor OPG were measured by ELISA in paired serum samples obtained from 66 patients with early RA at their first visit (baseline) and after 1 year of therapy. Levels of TRAIL and OPG were analyzed in relation to the clinical response, defined by the 28-joint count Disease Activity Score (DAS28). Results. Both serum TRAIL and OPG increased after DMARD therapy. Baseline levels of TRAIL, but not OPG, were significantly higher (p <0.05) in the patients that achieved a clinical response by DAS28 after 1 year of therapy, versus patients without clinical response to DMARD. Baseline serum levels of TRAIL were higher (p <0.01) in rheumatoid factor-negative patients. Conclusion. Our data suggest that the basal level of circulating TRAIL is an important determinant in the therapeutic response to DMARD in patients with early RA. The Journal of Rheumatology
AB - Objective. To assess the relationship between serum concentrations of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and osteoprotegerin (OPG) and the therapeutic response to disease-modifying antirheumatic drugs (DMARD) in patients with early rheumatoid arthritis (RA). Methods. Circulating levels of TRAIL and its soluble receptor OPG were measured by ELISA in paired serum samples obtained from 66 patients with early RA at their first visit (baseline) and after 1 year of therapy. Levels of TRAIL and OPG were analyzed in relation to the clinical response, defined by the 28-joint count Disease Activity Score (DAS28). Results. Both serum TRAIL and OPG increased after DMARD therapy. Baseline levels of TRAIL, but not OPG, were significantly higher (p <0.05) in the patients that achieved a clinical response by DAS28 after 1 year of therapy, versus patients without clinical response to DMARD. Baseline serum levels of TRAIL were higher (p <0.01) in rheumatoid factor-negative patients. Conclusion. Our data suggest that the basal level of circulating TRAIL is an important determinant in the therapeutic response to DMARD in patients with early RA. The Journal of Rheumatology
KW - Disease modifying antirheumatic drugs
KW - Early rheumatoid arthritis
KW - Tumor necrosis factor related apoptosis inducing ligand
UR - http://www.scopus.com/inward/record.url?scp=77954442902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954442902&partnerID=8YFLogxK
U2 - 10.3899/jrheum.091363
DO - 10.3899/jrheum.091363
M3 - Article
C2 - 20472926
AN - SCOPUS:77954442902
VL - 37
SP - 1461
EP - 1466
JO - Journal of Rheumatology
JF - Journal of Rheumatology
SN - 0315-162X
IS - 7
ER -